AZD9750

AZD9750 is a protein degrader developed by AstraZeneca. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: An AR-PROTAC that binds the androgen receptor and recruits it for proteasomal degradation, rather than simply inhibiting its function. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07336446, plans to enrol 300 participants with primary completion expected 2029-01-26. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.